Nautilus Biotechnology, Inc. (NAUT)
US — Healthcare Sector
Automate Your Wheel Strategy on NAUT
With Tiblio's Option Bot, you can configure your own wheel strategy including NAUT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NAUT
- Rev/Share 0.0
- Book/Share 1.5565
- PB 0.4702
- Debt/Equity 0.1509
- CurrentRatio 17.3616
- ROIC -0.3517
- MktCap 92315106.0
- FreeCF/Share -0.4684
- PFCF -1.5778
- PE -1.3314
- Debt/Assets 0.1289
- DivYield 0
- ROE -0.3187
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NAUT | Goldman | Neutral | Sell | -- | $1.75 | Dec. 5, 2024 |
News
About Nautilus Biotechnology, Inc. (NAUT)
- IPO Date 2020-08-07
- Website https://www.nautilus.bio
- Industry Biotechnology
- CEO Mr. Sujal M. Patel
- Employees 134
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.